来凯医药-B(02105):LAE102针对肥胖症治疗的IND临床方案修订版已递交美国FDA

智通财经
31 Mar

智通财经APP讯,来凯医药-B(02105)发布公告,本集团已就LAE102针对肥胖症治疗适应症,向美国食品药品监督管理局(美国FDA)提交新药临床试验申请(IND)临床方案修订版。

2024年4月,LAE102获得美国FDA的IND批准,用于治疗肥胖症患者。2024年11月,本集团与礼来公司(礼来)(NYSE:LLY)签订一项临床合作协议,旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究(美国I期临床试验)并承担相关费用。本集团保留LAE102的全球权益。美国I期临床试验预计将于2025年第二季度启动。

本集团致力于将这种精准治疗带给那些需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10